78% Increase in Intravascular
Ultrasound Systems Sales Boosts Volcano Quarterly Growth by 40%
|
 |
November 5, 2008. San Diego -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported that revenues for the third quarter of 2008 increased 40 percent over those in the third quarter of 2007. For the quarter ended September 30, 2008, Volcano reported revenues of $44.1 million versus revenues of $31.5 million in the same period a year ago. The company said that its financial performance was driven by a 78 percent increase in intravascular ultrasound (IVUS) system revenues and a 29 percent increase in IVUS disposable revenues year-over-year. For the third quarter of 2008, the company reported net income on a GAAP basis of $744,000, or $0.01 per diluted share, versus a net loss on a GAAP basis of $652,000 or $0.02 per share, in the third quarter of 2007. Weighted average
shares at the end of the quarter were 50.3 million versus 38.7 million a year ago, reflecting the impact of the company's equity offering that was completed in the fourth quarter of 2007. Excluding stock-based compensation expense of $2.5 million, the company reported net income of $3.3 million, or $0.06 per diluted share. In the third quarter of 2007, excluding stock-based compensation expense of $2.0 million, the company reported net income of $1.3 million, or $0.03 per diluted share. A reconciliation of the company's GAAP and non-GAAP results can be found in today's earnings news release on the company's website at http://www.volcanocorp.com. For the first nine months of 2008, Volcano reported revenues of $122.2 million, a 35 percent increase over revenues of $90.6 million in the same period a year ago. On a GAAP basis, the company reported a net loss of $15.1 million,
or $0.32 per share, compared with a net loss of $2.8 million, or $0.07 per share, in the same period a year ago. Excluding in-process research and development charges of $12.4 million, $2.9 million in due diligence, legal and accounting expenses related to a proposed acquisition that was not consummated, and stock-based compensation expense of $7.0 million, Volcano reported net income of $7.2 million, or $0.14 per diluted share, in the first nine months of 2008. Excluding stock-based compensation expense of $4.7 million, the company reported net income of $1.9 million, or $0.04 per diluted share, in the first nine months of 2007. "We continue to gain market share across all of our businesses and geographies, while realizing gross margin improvement and leveraging our operating expenses. As a result, we achieved profitability on a GAAP basis in the third quarter of 2008, and have
raised our outlook for earnings per share for the full year," said Scott Huennekens,
president and chief executive officer. "Through the first nine months of 2008, we have placed 537 of our IVUS consoles versus 420 in the first nine months a year ago, and now have more than 3,700 of our IVUS and Functional Measurement (FM) consoles placed worldwide. Helping to drive our growth is the leading-edge technology offered by our devices and Volcano's strong sales and market development initiatives. In addition, we are seeing an increasingly favorable environment for percutaneous coronary interventions and an ongoing flow of positive data, including that presented in a number of presentations at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting," Huennekens
noted. "At the same time," he added, "we
continue to be excited about our new product pipeline that will enable
us to address markets that are potentially larger than those we are currently
serving." Guidance
for 2008
The company updated its guidance for fiscal 2008. It now expects that
revenues will be at the upper end of its previous range of $164-$168 million,
which represents an increase of approximately 27 to 29 percent over full year
revenues in 2007. It now expects gross margin to be in the range of 62-63 percent
versus prior guidance of 60-61 percent. The company reiterated that it expects
operating expenses, including stock-based compensation, due diligence costs
recorded in the first quarter, the in-process research and development costs
of $12.4 million incurred in the first half of the year, ongoing expenses associated
with the development of technology acquired through the Novelis transaction
and approximately $3.1 million of intangible amortization, will be 74-76 percent
of revenues. For the full year 2008, the company expects that on a GAAP basis
it will record a net loss of $0.30-$0.32 per share versus prior guidance of
$0.33-$0.37 per share. The company expects to be profitable on a GAAP basis
in the fourth quarter of 2008. Excluding stock-based compensation expense of
approximately $10.0 million, due diligence and in- process research and development
costs, the company expects to report non-GAAP net income of $0.18-$0.20 per
diluted share. This compares with prior guidance for non-GAAP net income of
$0.14-$0.18 per share. Weighted average shares outstanding at year-end 2008
are expected to be approximately 47.4 million basic shares and 50.4 million
shares on a diluted basis. Conference
Call
The company will hold a conference call at 2 p.m., Pacific Standard Time
(5 p.m. Eastern Standard Time) today. The teleconference can be accessed by
calling (719) 325-4761, passcode 8632414, or via the company's website at http://www.volcanocorp.com.
Please dial in or access the webcast 10-15 minutes prior to the beginning of
the call. A replay of the conference call will be available through November
12 at (719) 457-0820, passcode 8632414, and via the company's website. Volcano
Corporation
Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices
designed to facilitate endovascular procedures, enhance the diagnosis of vascular
and structural heart disease and guide optimal therapies. The company's intravascular
ultrasound (IVUS) product line includes ultrasound consoles that can be integrated
directly into virtually any modern cath lab. Volcano IVUS offers unique features,
including both single-use phased array and rotational IVUS imaging catheters,
and advanced functionality options, such as VH(TM) tissue characterization
and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles
and single-use pressure and flow guide wires and is developing a line of ultra-high
resolution Optical Coherence Tomography (OCT) systems and catheters. Currently,
more than 3,700 Volcano IVUS and FM systems are installed worldwide, with approximately
half of its revenues coming from outside the United States. For more information,
visit the company's website at http://www.volcanocorp.com. Use
of Non-GAAP Financial Measures
This press release includes certain non-GAAP
financial information as defined by the U.S. Securities and Exchange Commission
Regulation G. Pursuant to the requirements of this regulation, a reconciliation
of this non-GAAP financial information to our financial statements as prepared
under generally accepted accounting principles in the United States (GAAP)
is included in this press release. Non-GAAP financial measures provide an indication
of our performance before certain charges. Our management believes that in
order to properly understand our short-term and long-term financial trends,
investors may wish to consider the impact of these charges. These charges result
from facts and circumstances that vary in frequency and/or impact on continuing
operations. Our management believes that these items should be excluded when
comparing our current operating results with those of prior periods as stock-
based compensation is a non-cash expense, in-process research and development
relates to the costs associated with the May 2008 acquisition of Novelis, Inc.,
and the December 2007 acquisition of CardioSpectra, Inc., and the acquisition
due diligence costs incurred in the first quarter of 2008 related to a proposed
acquisition that
was not consummated, are not reflective of our core operating activities. In
addition, our management uses results of operations before certain charges
to evaluate the operational performance of the company and as a basis for strategic
planning. Investors should note that the non-GAAP financial measures used by
the company may not be the same non- GAAP financial measures, and may not be
calculated in the same manner, as those of other companies. Investors should
consider these non-GAAP measures in addition to, and not as a substitute for,
financial performance measures in accordance with GAAP. Forward-Looking
Statements
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this release regarding Volcano's business that are not historical facts
may be considered "forward-looking statements," including statements regarding
the company's financial guidance for 2008, market adoption of the company's
technology, the impact of
clinical and other technical data, the success and timing of product development
and clinical trial programs, growth strategies and market development and product
sales. Forward-looking statements are based on management's current preliminary
expectations and are subject to risks and uncertainties, which may cause Volcano's
results to differ materially and adversely from the statements contained here.
Some of the potential risks and uncertainties that could cause actual results
to differ from the results predicted are detailed in the company's annual report
on Form 10-K, quarterly reports on Form 10-Q and other filings made with the
Securities and Exchange Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Volcano undertakes
no obligation to update any forward-looking statements to reflect new information,
events or circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
VOLCANO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
September 30, December 31,
2008 2007
Assets
Current assets:
Cash and cash equivalents $108,662 $122,913
Short-term available-for-sale
investments 68,049 66,205
Accounts receivable, net 25,036 27,976
Inventories, net 25,698 21,243
Prepaid expenses and other current
assets 4,965 3,997
Total current assets 232,410 242,334
Restricted cash 360 365
Property and equipment, net 19,900 13,692
Intangible assets, net 7,439 9,385
Other non-current assets 886 798
$260,995 $266,574
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $13,139 $11,077
Accrued compensation 9,502 9,083
Accrued expenses and other current
liabilities 7,441 6,600
Deferred revenues 4,419 5,360
Current maturities of long-term debt 58 120
Total current liabilities 34,559 32,240
Long-term debt 49 78
Deferred license fee 938 1,125
Other 142 194
Total liabilities 35,688 33,637
Stockholders' equity 225,307 232,937
$260,995 $266,574
VOLCANO CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
Revenues $44,118 $31,474 $122,242 $90,605
Cost of revenues 16,581 12,285 45,915 35,466
Gross profit 27,537 19,189 76,327 55,139
Operating expenses:
Selling, general and administrative 19,546 16,005 62,405 44,271
Research and development 6,879 4,837 18,823 15,241
In-process research and development - - 12,407 -
Amortization of intangibles 786 751 2,337 2,313
Total operating expenses 27,211 21,593 95,972 61,825
Operating income (loss) 326 (2,404) (19,645) (6,686)
Interest income 1,109 1,213 4,206 3,630
Interest expense (2) (32) (8) (193)
Exchange rate gain (loss) (441) 829 1,091 1,042
Income (loss) before provision for
income taxes 992 (394) (14,356) (2,207)
Provision for income taxes 248 258 707 626
Net income (loss) $744 $(652) $(15,063) $(2,833)
Net income (loss) per share - basic $0.02 $(0.02) $(0.32) $(0.07)
Net income (loss) per share -
diluted $0.01 $(0.02) $(0.32) $(0.07)
Weighted-average shares outstanding
- basic 47,456 38,694 47,236 38,368
Weighted-average shares outstanding
- diluted 50,323 38,694 47,236 38,368
VOLCANO CORPORATION
RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
(in thousands, except per share data)
(Unaudited)
Three Months Ended September 30, 2008
Stock-based
GAAP compensation Non-GAAP
results expense results
Revenues $44,118 $- $44,118
Cost of revenues 16,581 (222) 16,359
Gross profit 27,537 222 27,759
Operating expenses:
Selling, general and administrative 19,546 (1,798) 17,748
Research and development 6,879 (493) 6,386
Amortization of intangibles 786 - 786
Total operating expenses 27,211 (2,291) 24,920
Operating income 326 2,513 2,839
Interest income 1,109 - 1,109
Interest expense (2) - (2)
Exchange rate loss (441) - (441)
Income before provision for income
taxes 992 2,513 3,505
Provision for income taxes 248 - 248
Net income $744 $2,513 $3,257
Net income per share - basic $0.02 $0.05 $0.07
Net income per share - diluted $0.01 $0.05 $0.06
Weighted-average shares outstanding
- basic 47,456 47,456
Weighted-average shares outstanding
- diluted 50,323 50,323
Three Months Ended September 30, 2007
Stock-based
GAAP compensation Non-GAAP
results expense results
Revenues $31,474 $- $31,474
Cost of revenues 12,285 (181) 12,104
Gross profit 19,189 181 19,370
Operating expenses:
Selling, general and administrative 16,005 (1,437) 14,568
Research and development 4,837 (359) 4,478
Amortization of intangibles 751 - 751
Total operating expenses 21,593 (1,796) 19,797
Operating loss (2,404) 1,977 (427)
Interest income 1,213 - 1,213
Interest expense (32) - (32)
Exchange rate gain 829 - 829
Income (loss) before provision for
income taxes (394) 1,977 1,583
Provision for income taxes 258 - 258
Net income (loss) $(652) $1,977 $1,325
Net income (loss) per share - basic $(0.02) $0.05 $0.03
Net income (loss) per share -
diluted $(0.02) $0.05 $0.03
Weighted-average shares outstanding
- basic 38,694 38,694
Weighted-average shares outstanding
- diluted 38,694 41,710
VOLCANO CORPORATION
RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
(in thousands, except per share data)
(Unaudited)
Nine Months Ended September 30, 2008
Stock- In-
based process Acquisition
compensa- research due Non-
GAAP tion and diligence GAAP
results expense development costs results
Revenues $122,242 $- $- $- $122,242
Cost of revenues 45,915 (598) - - 45,317
Gross profit 76,327 598 - - 76,925
Operating expenses:
Selling, general and
administrative 62,405 (5,094) - (2,878) 54,433
Research and development 18,823 (1,305) - - 17,518
In-process research and
development 12,407 - (12,407) - -
Amortization of
intangibles 2,337 - - - 2,337
Total operating
expenses 95,972 (6,399) (12,407) (2,878) 74,288
Operating income (loss) (19,645) 6,997 12,407 2,878 2,637
Interest income 4,206 - - - 4,206
Interest expense (8) - - - (8)
Exchange rate gain 1,091 - - - 1,091
Income (loss) before
provision for income
taxes (14,356) 6,997 12,407 2,878 7,926
Provision for income taxes 707 - - - 707
Net income (loss) $(15,063) $6,997 $12,407 $2,878 $7,219
Net income (loss) per share
- basic $(0.32) $0.15 $0.26 $0.06 $0.15
Net income (loss) per share
- diluted $(0.32) $0.14 $0.25 $0.06 $0.14
Weighted-average shares
outstanding - basic 47,236 47,236
Weighted-average shares
outstanding - diluted 47,236 49,859
Nine Months Ended September 30, 2007
Stock- In-
based process Acquisition
compensa- research due Non-
GAAP tion and diligence GAAP
results expense development costs results
Revenues $90,605 $- $- $- $90,605
Cost of revenues 35,466 (434) - - 35,032
Gross profit 55,139 434 - - 55,573
Operating expenses:
Selling, general and
administrative 44,271 (3,486) - - 40,785
Research and development 15,241 (783) - - 14,458
Amortization of
intangibles 2,313 - - - 2,313
Total operating
expenses 61,825 (4,269) - - 57,556
Operating loss (6,686) 4,703 - - (1,983)
Interest income 3,630 - - - 3,630
Interest expense (193) - - - (193)
Exchange rate gain 1,042 - - - 1,042
Income (loss) before
provision for income
taxes (2,207) 4,703 - - 2,496
Provision for income taxes 626 - - - 626
Net income (loss) $(2,833) $4,703 $- $- $1,870
Net income (loss) per share
- basic $(0.07) $0.12 $- $- $0.05
Net income (loss) per share
- diluted $(0.07) $0.11 $- $- $0.04
Weighted-average shares
outstanding - basic 38,368 38,368
Weighted-average shares
outstanding - diluted 38,368 41,739
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP
financial information as defined by the U.S. Securities and Exchange Commission
Regulation G. Pursuant to the requirements of this regulation, a reconciliation
of this non-GAAP financial information to our financial statements as prepared
under generally accepted accounting principles in the United States (GAAP) is
included in this press release. Non-GAAP financial measures provide an indication
of our performance before certain charges. Our management believes that in order
to properly understand our short-term and long-term financial trends, investors
may wish to consider the impact of these charges. These charges result from facts
and circumstances that vary in frequency and/or impact on continuing operations.
Our management believes that these items should be excluded when comparing our
current operating results with those of prior periods as stock- based compensation
is a non-cash expense, in-process research and development relates to the costs
associated with the May 2008 acquisition of Novelis, Inc. and the December 2007
acquisition of CardioSpectra, Inc., and the acquisition due diligence costs incurred
in the first quarter of 2008 related to a proposed acquisition that was not consummated,
are not reflective of our core operating activities. In addition, our management
uses results of operations before certain charges to evaluate the operational
performance of the company and as a basis for strategic planning. Investors should
note that the non-GAAP financial measures used by the company may not be the
same non-GAAP financial measures, and may not be calculated in the same manner,
as those of other companies. Investors should consider these non-GAAP measures
in
addition to, and not as a substitute for, financial performance measures in accordance
with GAAP.
VOLCANO CORPORATION
REVENUE SUMMARY
(in millions)
(Unaudited)
Growth YTD Q3 YTD Q3
Q3 '08 Q3 '07 % '08 '07 Growth
IVUS Systems:
United States $5.6 $3.4 62% $15.3 $11.0 40%
Japan 2.5 0.5 376% 4.9 1.8 172%
Europe 1.8 1.5 24% 5.4 3.5 50%
Rest of World 0.7 0.5 38% 1.9 1.7 14%
Total IVUS Systems $10.6 $5.9 78% $27.5 $18.0 52%
IVUS Disposables:
United States $13.0 $10.1 30% $37.6 $28.8 31%
Japan 8.9 7.5 18% 24.7 20.3 22%
Europe 4.6 3.0 51% 13.0 9.0 44%
Rest of World 0.7 0.5 27% 2.2 1.6 35%
Total IVUS Disposables $27.2 $21.1 29% $77.5 $59.7 30%
FM:
United States $2.3 $1.4 63% $6.3 $4.5 40%
Japan 0.5 0.2 186% 0.9 1.1 -16%
Europe 1.7 1.5 19% 5.1 4.1 24%
Rest of World 0.4 0.2 94% 0.8 0.6 43%
Total FM $4.9 $3.3 51% $13.1 $10.3 28%
Other 1.4 1.2 25% 4.1 2.6 56%
Total $44.1 $31.5 40% $122.2 $90.6 35%
Source: Volcano Corporation
|